

Requested by SENATE COMMITTEE ON HEALTH CARE

**PROPOSED AMENDMENTS TO
SENATE BILL 192**

1 In line 2 of the printed bill, after “drugs” insert “; creating new pro-
2 visions; amending ORS 646A.689, 646A.693, 646A.694, 646A.695, 705.146 and
3 743.025 and section 9, chapter 598, Oregon Laws 2021; and prescribing an ef-
4 fective date”.

5 Delete lines 4 through 8 and insert:

6 **“SECTION 1. Section 2 of this 2023 Act is added to and made a part
7 of ORS 735.530 to 735.552.**

8 **“SECTION 2. (1) As used in this section:**

9 **“(a) ‘Carrier’ has the meaning given that term in ORS 743B.005.**

10 **“(b) ‘Manufacturer’ has the meaning given that term in ORS
11 646A.689.**

12 **“(c) ‘Prescription drug’ has the meaning given that term in ORS
13 646A.689.**

14 **“(2) Not later than June 1 of each calendar year, a pharmacy benefit
15 manager registered under ORS 735.532 shall file a report with the De-
16 partment of Consumer and Business Services. The report must con-
17 tain, for the immediately preceding calendar year, the aggregated
18 dollar amount of rebates, fees, price protection payments and any
19 other payments the pharmacy benefit manager received from man-
20 ufacturers:**

21 **“(a) Related to managing the pharmacy benefits for carriers issuing**

1 **health benefit plans in this state; and**

2 **“(b) That were:**

3 **“(A) Passed on to carriers issuing health benefit plans in this state**
4 **or enrollees at the point of sale of a prescription drug in this state;**

5 **or**

6 **“(B) Retained as revenue by the pharmacy benefit manager.**

7 **“(3) The report described in subsection (2) of this section may not**
8 **disclose:**

9 **“(a) The identity of a carrier or an enrollee;**

10 **“(b) The price charged for a specific prescription drug or class of**
11 **drugs; or**

12 **“(c) The amount of any rebate or fee provided for a specific pre-**
13 **scription drug or class of prescription drugs.**

14 **“(4) Information submitted to the department under this section is**
15 **confidential and not subject to disclosure except as provided in sub-**
16 **section (5) of this section and ORS 705.137.**

17 **“(5) Not later than October 1 of each calendar year, the department**
18 **shall publish on the department’s website the aggregated data from**
19 **all reports filed by pharmacy benefit managers under this section for**
20 **the preceding calendar year. The department shall publish the data in**
21 **a manner that does not disclose confidential information of pharmacy**
22 **benefit managers.**

23 **“SECTION 3. ORS 705.146 is amended to read:**

24 **“705.146. The Prescription Drug Affordability Account is established as a**
25 **subaccount in the Consumer and Business Services Fund created in ORS**
26 **705.145, consisting of moneys collected under ORS 646A.695 and moneys that**
27 **may be appropriated for deposit into the Prescription Drug Affordability**
28 **Account by the Legislative Assembly. Interest earned on the account shall**
29 **be credited to the account. Moneys in the account are continuously appro-**
30 **priated to the [*Prescription Drug Affordability Board*] **Department of Con-****

1 **sumer and Business Services** to carry out ORS 646A.693 to 646A.695.

2 **“SECTION 4.** ORS 646A.689 is amended to read:

3 “646A.689. (1) As used in [*this section and*] ORS 646A.693 to 646A.695:

4 “(a) ‘Drug’ has the meaning given that term in ORS 689.005.

5 “(b) ‘Health care facility’ has the meaning given that term in ORS 442.015.

6 “(c) ‘Health care service contractor’ has the meaning given that term in
7 ORS 750.005.

8 “(d)(A) ‘Manufacture’ means:

9 “(i) The production, preparation, propagation, compounding, conversion
10 or processing of a drug, either directly or indirectly by extraction from sub-
11 stances of natural origin or independently by means of chemical synthesis,
12 or by a combination of extraction and chemical synthesis; and

13 “(ii) The packaging or repackaging of a drug or labeling or relabeling of
14 a drug container.

15 “(B) ‘Manufacture’ does not include the preparation or compounding of
16 a drug by an individual for the individual’s own use or the preparation,
17 compounding, packaging or labeling of a drug:

18 “(i) By a health care practitioner incidental to administering or dispens-
19 ing a drug in the course of professional practice;

20 “(ii) By a health care practitioner or at the practitioner’s authorization
21 and supervision for the purpose of or incidental to research, teaching or
22 chemical analysis activities and not for sale;

23 “(iii) By a health care service contractor for dispensing to a subscriber
24 or delivery to a health care facility or outpatient clinic owned or operated
25 by the health care service contractor or an affiliate of the health care service
26 contractor;

27 “(iv) By a centralized repackaging operation for distribution to subscrib-
28 ers of health care service contractors or to pharmacies, health care facilities
29 or outpatient clinics operated by or affiliated with a health care service
30 contractor; or

1 “(v) By a health care facility for dispensing to a patient or other person.

2 “(e) ‘Manufacturer’ means a person that manufactures a prescription drug
3 that is sold in this state.

4 “(f) ‘New prescription drug’ has the meaning prescribed by the Depart-
5 ment of Consumer and Business Services by rule.

6 “(g) ‘Patient assistance program’ means a program that a manufacturer
7 offers to the general public in which a consumer may reduce the consumer’s
8 out-of-pocket costs for prescription drugs by using coupons or discount cards,
9 receiving copayment assistance or by other means.

10 “(h) ‘Prescription drug’ means a drug that must:

11 “(A) Under federal law, be labeled ‘Caution: Federal law prohibits dis-
12 pensing without prescription’ prior to being dispensed or delivered; or

13 “(B) Under any applicable federal or state law or regulation, be dispensed
14 only by prescription or restricted to use only by health care practitioners.

15 “(i) ‘Price’ means the wholesale acquisition cost as defined in 42 U.S.C.
16 1395w-3a(c)(6)(B).

17 “(2) No later than March 15 of each year, a manufacturer shall report the
18 information described in subsection (3) of this section to the department re-
19 garding each prescription drug for which:

20 “(a) The price was \$100 or more for a one-month supply or for a course
21 of treatment lasting less than one month; and

22 “(b) There was a net increase of 10 percent or more in the price of the
23 prescription drug described in paragraph (a) of this subsection over the
24 course of the previous calendar year.

25 “(3) For each prescription drug described in subsection (2) of this section,
26 a manufacturer shall report to the department, in the form and manner pre-
27 scribed by the department:

28 “(a) The name and price of the prescription drug and the net increase,
29 expressed as a percentage, in the price of the drug over the course of the
30 previous calendar year;

1 “(b) The length of time the prescription drug has been on the market;
2 “(c) The factors that contributed to the price increase;
3 “(d) The name of any generic version of the prescription drug available
4 on the market;
5 “(e) The research and development costs associated with the prescription
6 drug that were paid using public funds;
7 “(f) The direct costs incurred by the manufacturer:
8 “(A) To manufacture the prescription drug;
9 “(B) To market the prescription drug;
10 “(C) To distribute the prescription drug; and
11 “(D) For ongoing safety and effectiveness research associated with the
12 prescription drug;
13 “(g) The total sales revenue for the prescription drug during the previous
14 calendar year;
15 “(h) The manufacturer’s profit attributable to the prescription drug dur-
16 ing the previous calendar year;
17 “(i) The introductory price of the prescription drug when it was approved
18 for marketing by the United States Food and Drug Administration and the
19 net yearly increase, by calendar year, in the price of the prescription drug
20 during the previous five years;
21 “(j) The 10 highest prices paid for the prescription drug during the pre-
22 vious calendar year in any country other than the United States;
23 “(k) Any other information that the manufacturer deems relevant to the
24 price increase described in subsection (2)(b) of this section; and
25 “(L) The documentation necessary to support the information reported
26 under this subsection.
27 “(4) The department may use any prescription drug price information the
28 department deems appropriate to verify that manufacturers have properly
29 reported price increases as required by subsections (2) and (3) of this section.
30 “(5) **No later than March 15 of each year**, a manufacturer shall [*ac-*

1 *company the]* report [*provided under subsection (2) of this section with]* the
2 following information about each patient assistance program offered **or**
3 **funded** by the manufacturer **that provided patient assistance** to consum-
4 ers residing in this state [*for the prescription drugs described in subsection*
5 *(2) of this section]* **during the prior calendar year:**

6 “(a) The number of consumers who participated in the program;

7 “(b) The total value of the coupons, discounts, copayment assistance or
8 other reduction in costs provided to consumers in this state who participated
9 in the program;

10 “(c) For each drug, the number of refills that qualify for the program, if
11 applicable;

12 “(d) If the program expires after a specified period of time, the period of
13 time that the program is available to each consumer; and

14 “(e) The eligibility criteria for the program and how eligibility is verified
15 for accuracy.

16 “(6) No later than 30 days after a manufacturer introduces a new pre-
17 scription drug for sale in the United States at a price that exceeds the
18 threshold established by the Centers for Medicare and Medicaid Services for
19 specialty drugs in the Medicare Part D program, the manufacturer shall no-
20 tify the department, in the form and manner prescribed by the department,
21 of all the following information:

22 “(a) A description of the marketing used in the introduction of the new
23 prescription drug;

24 “(b) The methodology used to establish the price of the new prescription
25 drug;

26 “(c) Whether the United States Food and Drug Administration granted
27 the new prescription drug a breakthrough therapy designation or a priority
28 review;

29 “(d) If the new prescription drug was not developed by the manufacturer,
30 the date of and the price paid for acquisition of the new prescription drug

1 by the manufacturer;

2 “(e) The manufacturer’s estimate of the average number of patients who
3 will be prescribed the new prescription drug each month; and

4 “(f) The research and development costs associated with the new pre-
5 scription drug that were paid using public funds.

6 “(7)(a) After receiving the report or information described in subsection
7 (2), (3), (5) or (6) of this section, the department may make a written request
8 to the manufacturer for supporting documentation or additional information
9 concerning the report. The department shall prescribe by rule the periods:

10 “(A) Following the receipt of the report or information during which the
11 department may request additional information; and

12 “(B) Following a request by the department for additional information
13 during which a manufacturer may respond to the request.

14 “(b) The department may extend the period prescribed under paragraph
15 (a)(B) of this subsection, as necessary, on a case-by-case basis.

16 “(8) A manufacturer may be subject to a civil penalty, as provided in ORS
17 646A.692, for:

18 “(a) Failing to submit timely reports or notices as required by this sec-
19 tion;

20 “(b) Failing to provide information required under this section;

21 “(c) Failing to respond in a timely manner to a written request by the
22 department for additional information under subsection (7) of this section;
23 or

24 “(d) Providing inaccurate or incomplete information under this section.

25 “(9) Except as provided in subsection (10) of this section, the department
26 shall post to its website all of the following information:

27 “(a) A list of the prescription drugs reported under subsection (2) of this
28 section and the manufacturers of those prescription drugs;

29 “(b) Information reported to the department under subsections (3) and (5)
30 to (7) of this section; and

1 “(c) Written requests by the department for additional information under
2 subsection (7) of this section.

3 “(10)(a) The department may not post to its website any information de-
4 scribed in subsection (9) of this section if:

5 “(A) The information is conditionally exempt from disclosure under ORS
6 192.345 as a trade secret; and

7 “(B) The public interest does not require disclosure of the information.

8 “(b) If the department withholds any information from public disclosure
9 pursuant to this subsection, the department shall post to its website a report
10 describing the nature of the information and the department’s basis for
11 withholding the information from disclosure.

12 “(c) A person may petition the Attorney General, as provided in ORS
13 192.411, to review a decision by the department to withhold information
14 pursuant to paragraph (a) of this subsection.

15 “(11) In accordance with ORS 646A.694, the department shall provide to
16 the Prescription Drug Affordability Board established in ORS 646A.693:

17 “(a) Each calendar quarter, a list of prescription drugs included in reports
18 submitted under subsections (2) and (6) of this section; and

19 “(b) Access to pricing information submitted to the department under
20 subsections (3), (6) and (7) of this section.

21 “(12) The department shall make available to consumers, online and by
22 telephone, a process for consumers to notify the department about an in-
23 crease in the price of a prescription drug. **Any personally identifiable in-**
24 **formation about a consumer included in a notification provided to the**
25 **department under this subsection, such as a consumer’s name, ad-**
26 **dress, telephone number or electronic mail address, is confidential and**
27 **not subject to disclosure under ORS 192.311 to 192.478.**

28 “(13) The department may adopt rules as necessary for carrying out the
29 provisions of this section[, *including but not limited to rules establishing fees*
30 *to be paid by manufacturers to be used solely to pay the costs of the department*

1 *in carrying out the provisions of this section].*

2 “(14) No later than December 15 of each year, the department shall com-
3 pile and report the information collected by the department under this sec-
4 tion to the interim committees of the Legislative Assembly related to health.
5 The report shall include recommendations for legislative changes, if any, to
6 contain the cost of prescription drugs and reduce the impact of price in-
7 creases on consumers, the Department of Corrections, the Public Employees’
8 Benefit Board, the Oregon Health Authority, the Department of Human
9 Services, the Oregon Educators Benefit Board and health insurance premi-
10 ums in the commercial market.

11 **“SECTION 5.** ORS 646A.693 is amended to read:

12 “646A.693. (1) The Prescription Drug Affordability Board is established in
13 the Department of Consumer and Business Services to protect residents of
14 this state, state and local governments, commercial health plans, health care
15 providers, pharmacies licensed in this state and other stakeholders within
16 the health care system in this state from the high costs of prescription drugs.

17 “(2) The board consists of [*five*] **eight** members [*and three alternates*] ap-
18 pointed by the Governor.

19 “(3) The term of office of each member of the board is four years, but a
20 member serves at the pleasure of the Governor. Before the expiration of the
21 term of a member, the Governor shall appoint a successor whose term begins
22 on January 1 next following. A member is eligible for reappointment. If there
23 is a vacancy for any cause, the Governor shall make an appointment to be-
24 come immediately effective for the unexpired term.

25 “(4) The appointment of each member of the board is subject to confir-
26 mation by the Senate in the manner prescribed in ORS 171.562 and 171.565.

27 “(5) A member of the board is entitled to compensation and expenses as
28 provided in ORS 292.495.

29 “(6) The members of the board must be residents of this state with ex-
30 pertise in health care economics and clinical medicine.

1 “(7) A member of the board may not be an employee of, a board member
2 of or a consultant to a manufacturer or a trade association of manufacturers.

3 “(8) The board shall select one of its members as chairperson and another
4 as vice chairperson, for terms and with duties and powers necessary for the
5 performance of the functions of the offices as the board determines.

6 “(9) A majority of the members of the board constitutes a quorum for the
7 transaction of business.

8 “(10) The department shall appoint an executive director for the board,
9 may employ consultants, investigators or other staff and shall provide staff
10 support to the board to carry out its duties.

11 “(11) The board shall meet at least once every six weeks at a time and
12 place determined by the chairperson. The chairperson may cancel or postpone
13 a regular meeting if there is no prescription drug to review. The board may
14 also meet at other times and places specified by the call of the chairperson
15 or of a majority of the members of the board.

16 “(12)(a) The following actions by the board shall be open to the public in
17 accordance with ORS 192.610 to 192.690:

18 “(A) Any deliberation on whether to conduct an affordability review of
19 a prescription drug under ORS [646A.695] **646A.694**; and

20 “(B) Any decision or deliberation toward a decision on any matter before
21 the board except as provided in paragraph (b) of this subsection.

22 “(b) The board may meet in executive session to discuss trade secret in-
23 formation.

24 “(13) The board shall:

25 “(a) Provide public notice of each board meeting at least two weeks in
26 advance of the meeting;

27 “(b) Make materials for each board meeting available to the public at
28 least one week in advance of the meeting;

29 “(c) Provide an opportunity for public comment at each open meeting of
30 the board; and

1 “(d) Provide the public with the opportunity to submit written comments
2 on any pending decision of the board.

3 “(14) The board may allow expert testimony at board meetings, including
4 when the board meets in executive session.

5 “(15)(a) A member of the board shall recuse the member from decisions
6 related to a prescription drug if the member, or an immediate family member
7 of the member, has received or could receive any of the following:

8 “(A) A direct financial benefit of any amount deriving from the result or
9 finding of a study, review or determination by or for the board; or

10 “(B) A financial benefit from any person that owns, manufactures, or
11 provides prescription drugs, services or items to be reviewed by the board
12 that in the aggregate exceeds \$5,000 per year.

13 “(b) For the purposes of paragraph (a) of this subsection, a financial
14 benefit includes honoraria, fees, stock, the value of the member’s or imme-
15 diate family member’s stock holdings and any direct financial benefit deriv-
16 ing from the result or finding of a study, review or determination by or for
17 the board.

18 “(c) A conflict of interest shall be disclosed:

19 “(A) By the board when hiring board staff;

20 “(B) By the Governor when appointing members [*and alternate members*]
21 to the board; and

22 “(C) By the board, when a member of the board is recused in any final
23 decision resulting from a review of a prescription drug.

24 “(d) A conflict of interest shall be disclosed at the earlier of:

25 “(A) Prior to the first board meeting after the conflict is identified; or

26 “(B) Within five days after the conflict is identified.

27 “(e) A conflict of interest disclosed under this section shall be posted on
28 the website of the board unless the chairperson of the board recuses the
29 member from any final decision resulting from a review of a prescription
30 drug.

1 “(f) A posting under paragraph (e) of this subsection shall include the
2 type, nature and magnitude of the conflict of interest of the member in-
3 volved.

4 “(16) Members [*and alternate members*] of the board, staff and third par-
5 ties that contract with the board may not accept any gift or donation of
6 services or property that creates a potential conflict of interest or has the
7 appearance of biasing the work of the board.

8 “(17)(a) The board may enter into a contract with a qualified, independent
9 third party for any service necessary to carry out the powers and duties of
10 the board.

11 “(b) Unless permission is granted by the board, a third party hired by the
12 board may not release, publish or otherwise use any information to which
13 the third party has access under its contract.

14 “(18) In accordance with applicable provisions of ORS chapter 183, the
15 board may adopt rules necessary for the administration of ORS 646A.693 to
16 646A.695.

17 “**SECTION 6.** Section 9, chapter 598, Oregon Laws 2021, is amended to
18 read:

19 “**Sec. 9.** Notwithstanding the term of office specified by section 1 [*of this*
20 *2021 Act*], **chapter 598, Oregon Laws 2021**, of the members first appointed
21 to the Prescription Drug Affordability Board:

22 “(1) [*One member and one alternate*] **Two members** shall serve for a term
23 ending December 31, 2024.

24 “(2) [*Two*] **Three** members [*and one alternate*] shall serve for a term end-
25 ing December 31, 2025.

26 “(3) [*Two*] **Three** members, including the chairperson, [*and one alternate*]
27 shall serve for a term ending December 31, 2026.

28 “**SECTION 7.** ORS 646A.694 is amended to read:

29 “646A.694. (1) The Department of Consumer and Business Services shall
30 provide to the Prescription Drug Affordability Board each calendar quarter

1 a list of prescription drugs included in reports submitted to the department
2 under ORS 646A.689 (2) and (6), a list of drugs included in reports submitted
3 to the department under ORS **646A.683 and** 743.025 and a list of insulin
4 drugs marketed in this state during the previous calendar year. Each cal-
5 endar year, the board shall identify nine drugs and at least one insulin
6 product from the lists provided under this subsection that the board deter-
7 mines may create affordability challenges for health care systems or high
8 out-of-pocket costs for patients in this state based on criteria adopted by the
9 board by rule, including but not limited to:

10 “(a) Whether the prescription drug has led to health inequities in com-
11 munities of color;

12 “(b) The number of residents in this state prescribed the prescription
13 drug;

14 “(c) The price for the prescription drug sold in this state;

15 “(d) The estimated average monetary price concession, discount or rebate
16 the manufacturer provides to health insurance plans in this state or is ex-
17 pected to provide to health insurance plans in this state, expressed as a
18 percentage of the price for the prescription drug under review;

19 “(e) The estimated total amount of the price concession, discount or re-
20 bate the manufacturer provides to each pharmacy benefit manager registered
21 in this state for the prescription drug under review, expressed as a percent-
22 age of the prices;

23 “(f) The estimated price for therapeutic alternatives to the drug that are
24 sold in this state;

25 “(g) The estimated average price concession, discount or rebate the man-
26 ufacturer provides or is expected to provide to health insurance plans and
27 pharmacy benefit managers in this state for therapeutic alternatives;

28 “(h) The estimated costs to health insurance plans based on patient use
29 of the drug consistent with the labeling approved by the United States Food
30 and Drug Administration and recognized standard medical practice;

1 “(i) The impact on patient access to the drug considering standard pre-
2 scription drug benefit designs in health insurance plans offered in this state;

3 “(j) The relative financial impacts to health, medical or social services
4 costs as can be quantified and compared to the costs of existing therapeutic
5 alternatives;

6 “(k) The estimated average patient copayment or other cost-sharing for
7 the prescription drug in this state;

8 “(L) Any information a manufacturer chooses to provide; and

9 “(m) Any other factors as determined by the board in rules adopted by the
10 board.

11 “(2) A drug that is designated by the Secretary of the United States Food
12 and Drug Administration, under 21 U.S.C. 360bb, as a drug for a rare disease
13 or condition is not subject to review under subsection (1) of this section.

14 “(3) The board shall accept testimony from patients and caregivers af-
15 fected by a condition or disease that is treated by a prescription drug under
16 review by the board and from individuals with scientific or medical training
17 with respect to the disease or condition.

18 “(4)(a) If the board considers the cost-effectiveness of a prescription drug
19 in criteria adopted by the board under subsection (1) of this section, the
20 board may not use quality-adjusted life-years, or similar formulas that take
21 into account a patient’s age or severity of illness or disability, to identify
22 subpopulations for which a prescription drug would be less cost-effective. For
23 any prescription drug that extends life, the board’s analysis of cost-
24 effectiveness must weigh the value of the quality of life equally for all pa-
25 tients, regardless of the patients’ age or severity of illness or disability.

26 “(b) As used in this subsection:

27 “(A) ‘Health utility’ means a measure of the degree to which having a
28 particular form of disease or disability or having particular functional limi-
29 tations negatively impacts the quality of life as compared to a state of per-
30 fect health, expressed as a number between zero and one.

1 “(B) ‘Quality-adjusted life-year’ is the product of a health utility multi-
2 plied by the extra months or years of life that a patient might gain as a re-
3 sult of a treatment.

4 “(5) To the extent practicable, the board shall access pricing information
5 for prescription drugs by:

6 “(a) Accessing pricing information collected by the department under ORS
7 646A.689 and 743.025;

8 “(b) Accessing data reported to the Oregon Health Authority under ORS
9 442.373;

10 “(c) Entering into a memorandum of understanding with another state to
11 which manufacturers already report pricing information; and

12 “(d) Accessing other publicly available pricing information.

13 “(6) The information used to conduct an affordability review may include
14 any document and research related to the introductory price or price in-
15 crease of a prescription drug, including life cycle management, net average
16 price in this state, market competition and context, projected revenue and
17 the estimated value or cost-effectiveness of the prescription drug.

18 “(7) The department and the board shall keep strictly confidential any
19 information collected, used or relied upon for the review conducted under
20 this section if the information is:

21 “(a) Information submitted to the department by a manufacturer under
22 ORS 646A.689; and

23 “(b) Confidential, proprietary or a trade secret as defined in ORS 192.345.

24 “**SECTION 8.** ORS 646A.695 is amended to read:

25 “646A.695. (1) The Department of Consumer and Business Services shall
26 adopt by rule, in consultation with the Prescription Drug Affordability
27 Board, annual fees to be paid by manufacturers [*that sell*] **of** prescription
28 drugs **that are sold** in this state. The fees shall be established in amounts
29 necessary to meet the costs of the department [*and the board*] in adminis-
30 tering ORS 646A.693 to 646A.695. [*The fees shall be imposed based on a*

1 *manufacturer's share of gross revenue from sales of prescription drugs in this*
2 *state.]*

3 “(2) Fees collected under this section shall be deposited in the Pre-
4 scription Drug Affordability Account established in ORS 705.146.

5 **“SECTION 9.** ORS 743.025 is amended to read:

6 **“743.025. (1) As used in this section, ‘health benefit plan’ has the**
7 **meaning given that term in ORS 743B.005.**

8 “[*(1)*] **(2)** An insurer shall [*include with any filing under ORS 743.018*]
9 **annually report** the following information **to the Department of Con-**
10 **sumer and Business Services, in the form and manner prescribed by**
11 **the department,** regarding drugs reimbursed by the insurer under [*policies*
12 *or certificates*] **health benefit plans issued by the insurer** in this state:

13 “(a) The 25 most frequently prescribed drugs;

14 “(b) The 25 most costly drugs as a portion of total annual spending;

15 “(c) The 25 drugs that have caused the greatest increase in total plan
16 spending from one year to the next; and

17 “(d) The impact of the costs of prescription drugs on premium rates.

18 “[*(2)*] **(3)** The department [*of Consumer and Business Services*] shall con-
19 duct a public hearing annually on prescription drug prices, information re-
20 ported to the department under ORS 646A.689 and information described in
21 subsection [*(1)*] **(2)** of this section.

22 “[*(3)*] **(4)** The department shall regularly update the interim committees
23 of the Legislative Assembly related to health on the information described
24 in subsection [*(1)*] **(2)** of this section.

25 “[*(4)*] **(5)** Subsection [*(1)*] **(2)** of this section applies to an insurer that is-
26 sues [*policies or certificates of health insurance*] **health benefit plans** for sale
27 in this state that include a prescription drug benefit.

28 **“SECTION 10.** ORS 646A.680, 646A.683, 646A.686, 646A.689, 646A.692,
29 **646A.696 and 646A.697 are added to and made a part of ORS 646A.693**
30 **to 646A.695.**

1 **“SECTION 11. This 2023 Act takes effect on the 91st day after the**
2 **date on which the 2023 regular session of the Eighty-second Legislative**
3 **Assembly adjourns sine die.”.**

4
